Opicapone

CAS No. 923287-50-7

Opicapone ( BIA 9-1067 )

Catalog No. M24972 CAS No. 923287-50-7

Opicapone reduces the ATP content of the cells (IC50: 98 μM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 77 In Stock
5MG 129 In Stock
10MG 219 In Stock
25MG 401 In Stock
50MG 592 In Stock
100MG 844 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Opicapone
  • Note
    Research use only, not for human use.
  • Brief Description
    Opicapone reduces the ATP content of the cells (IC50: 98 μM).
  • Description
    Opicapone reduces the ATP content of the cells (IC50: 98 μM). Opicapone is an effective third-generation catechol-O-methyltransferase inhibitor for the research of Parkinson's disease and motor fluctuations.
  • Synonyms
    BIA 9-1067
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Transferase
  • Recptor
    COMT
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    923287-50-7
  • Formula Weight
    413.2
  • Molecular Formula
    C15H10Cl2N4O6
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:100 mg/mL (242.03 mM; Need ultrasonic)
  • SMILES
    OC1=CC(C2=NC(C3=C(Cl)[N+]([O-])=C(C)C(Cl)=C3C)=NO2)=CC([N+]([O-])=O)=C1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Bonifácio MJ, et al. Pharmacological profile of Opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol. 2015 Apr;172(7):1739-52.
molnova catalog
related products
  • CP-609754

    CP-609754 shows selective inhibition of farnesyltransferase.

  • Eliglustat

    Eliglustat (Tartrate) inhibitsglucosylceramide synthase(GCS),thus reducing the load of glucosylceramide influx into the lysosome.

  • FGTI-2734

    FGTI-2734 can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors.?